FDA Approved: DEFERASIROX — Supplemental Application (Bionpharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for Deferasirox from Bionpharma Inc. under an ANDA, authorizing an additional regulatory action for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload
• Myelodysplastic Syndrome
• Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

SUPPL AP for DEFERASIROX (DEFERASIROX)